Veterinary and comparative oncology 17(2) 184-193 2019年6月 [査読有り]
Canine histiocytic sarcoma is an aggressive, fatal neoplastic disease with a poor prognosis. Lomustine is generally accepted as the first-line systemic therapy, although this compound does not provide complete regression. Therefore, research into ...
R Miyamoto   S Kurita   H Tani   T Ikeda   M Ishizaka   H Saima   M Kobayashi   K Tamura   M Bonkobara   
Veterinary journal (London, England : 1997) 240 31-36 2018年10月 [査読有り]
Treatment of unresectable canine squamous cell carcinoma (SCC) remains challenging and new therapeutic strategies are needed. Survivin is a member of the inhibitor of apoptosis protein family and its inhibitor, YM155, is a potential anti-tumour ag...
Veterinary immunology and immunopathology 201 72-76 2018年7月 [査読有り]
Feline histiocytic sarcoma (HS) is an aggressive and uncommon tumor originating from dendritic cells/macrophages. Here, a feline HS cell line, FHS-1, was established from a case of feline HS and characterized. Immunohistochemically, FHS-1 cells we...
K Ito   R Miyamoto   H Tani   S Kurita   M Kobayashi   K Tamura   M Bonkobara   
Journal of veterinary pharmacology and therapeutics 41(1) e45-e48-e48 2018年2月 [査読有り]
Canine histiocytic sarcoma (HS) is an aggressive and highly metastatic tumor. Previously, the kinase inhibitor dasatinib was shown to have potent growth inhibitory activity against HS cells in vitro, possibly via targeting the EPHA2 receptor. Here...